Railway Pension Investments Ltd Buys 900 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Railway Pension Investments Ltd raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 99,700 shares of the pharmaceutical company’s stock after purchasing an additional 900 shares during the period. Railway Pension Investments Ltd’s holdings in Vertex Pharmaceuticals were worth $41,676,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. University of Texas Texas AM Investment Managment Co. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $25,000. Arlington Trust Co LLC increased its stake in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 33 shares during the period. Annapolis Financial Services LLC acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth about $27,000. ICA Group Wealth Management LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Baystate Wealth Management LLC grew its holdings in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VRTX. Wells Fargo & Company increased their price objective on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. Piper Sandler increased their price target on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a report on Friday. Oppenheimer restated an “outperform” rating and issued a $500.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, April 15th. TD Cowen upped their price objective on shares of Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price on the stock in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $472.23.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock traded down $11.32 during trading hours on Friday, hitting $494.46. 1,554,817 shares of the stock were exchanged, compared to its average volume of 1,047,953. Vertex Pharmaceuticals Incorporated has a 12 month low of $340.20 and a 12 month high of $510.64. The business’s 50-day moving average is $479.25 and its two-hundred day moving average is $439.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. The stock has a market capitalization of $127.60 billion, a P/E ratio of 32.09 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. The firm had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a negative return on equity of 2.36% and a negative net margin of 4.74%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $2.67 EPS. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.04 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total transaction of $2,689,860.00. Following the sale, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Reshma Kewalramani sold 1,565 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $457.00, for a total transaction of $715,205.00. Following the transaction, the chief executive officer now owns 121,374 shares of the company’s stock, valued at $55,467,918. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at $20,320,000. The disclosure for this sale can be found here. Insiders sold 53,423 shares of company stock valued at $25,528,865 over the last ninety days. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.